Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply

Affiliations

¹ Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
² Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
³ John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
⁴ Department of Internal Medicine, Medical College of Virginia, Richmond, Virginia, USA.
⁵ Swedish Medical Group, Seattle, Washington, USA.
⁶ Division of Gastroenterology and Hepatology, Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA.
⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
⁸ Division of Gastroenterology, Hepatology, and Nutrition, Duke University, Durham, North Carolina, USA.
⁹ Division of Gastroenterology and Liver, Keck Medicine, University of Southern California, Los Angeles, California, USA.
¹⁰ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
¹¹ NAFLD Research Center, Department of Medicine, University of California San Diego, San Diego, California, USA.
¹² Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
¹³ Analytic Pathology Medical Group, Sharp Memorial Hospital, San Diego, California, USA.

Comment

Danielle Brandman et al. Aliment Pharmacol Ther. 2022 Jul.

. 2022 Jul;56(1):182-183.

doi: 10.1111/apt.16972.

¹ Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
² Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
³ John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
⁴ Department of Internal Medicine, Medical College of Virginia, Richmond, Virginia, USA.
⁵ Swedish Medical Group, Seattle, Washington, USA.
⁶ Division of Gastroenterology and Hepatology, Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA.
⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
⁸ Division of Gastroenterology, Hepatology, and Nutrition, Duke University, Durham, North Carolina, USA.
⁹ Division of Gastroenterology and Liver, Keck Medicine, University of Southern California, Los Angeles, California, USA.
¹⁰ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
¹¹ NAFLD Research Center, Department of Medicine, University of California San Diego, San Diego, California, USA.
¹² Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
¹³ Analytic Pathology Medical Group, Sharp Memorial Hospital, San Diego, California, USA.

No abstract available

Comment on

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Brandman D, et al. Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17. Aliment Pharmacol Ther. 2022. PMID: 35302256 Free PMC article.
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD - not everyone fits the mould.
Giri S, Agrawal D, Afzalpurkar S. Giri S, et al. Aliment Pharmacol Ther. 2022 Jul;56(1):180-181. doi: 10.1111/apt.16931. Aliment Pharmacol Ther. 2022. PMID: 35689312 No abstract available.

1. Dhiraj GSA, Afzalpurkar S. Letter: non-invasive prediction models to exclude cirrhosis in NAFLD - not everyone fits the mould. Aliment Pharmacol Ther. 2022;56:180-181.
1. Brandman D, Boyle M, McPherson S, et al. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2022;55:1441-51.
1. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-78 e5; quiz e14-5. https://doi.org/10.1053/j.gastro.2015.04.005
1. Aveyard P, Lewis A, Tearne S, et al. Screening and brief intervention for obesity in primary care: a parallel, two-arm, randomised trial. Lancet. 2016;388(10059):2492-500. https://doi.org/10.1016/S0140-6736(16)31893-1
1. Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, et al. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38(10):1793-802. https://doi.org/10.1111/liv.13739